BioX­cel stock craters af­ter dis­clo­sure of in­ves­ti­ga­tor's fal­si­fied safe­ty re­port in Alzheimer's study

BioX­cel tout­ed da­ta Thurs­day morn­ing claim­ing that Igal­mi, its drug for ag­i­ta­tion episodes, suc­ceed­ed in a piv­otal tri­al with Alzheimer’s pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.